Reserpine
- Atc Codes:C02AA02
- CAS Codes:50-55-5
- PHARMGKB ID:50-55-5
Table of contents
- Brand Names
- Drug Combinations
- Chemistry
- Pharmacologic Category
- Mechanism of Action
- Therapeutic Use
- Unlabeled Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Inhibits
- Induces
- Drug Interactions
- Nutrition/Nutraceutical Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Italy: Reserpin; Poland: Raupasil.
Asia
Japan: Apoplon, Reserpine.
Drug combinations
Reserpine and Clopamide
Reserpine and Hydrochlorothiazide
Reserpine and Mefruside
Reserpine, Clopamide, and Ergoloid Mesylates
Chemistry
Reserpine: C~33~H~40~N~2~O~9~. Mw: 608.68. (1) Yohimban-16-carboxylic acid, 11,17-dimethoxy-18-[(3,4,5-trimethoxybenzoyl)oxy]-, methyl ester, (3β,16β,17α,18β,20α)-; (2) Methyl 18β-hydroxy-11,17α-dimethoxy-3β,20α-yohimban-16β-carboxylate 3,4,5-trimethoxybenzoate (ester). CAS-50-55-5.
Pharmacologic Category
Hypotensive Agents, Miscellaneous. Central Monoamine-Depleting Agent, Rauwolfia Alkaloid. (ATC-Code: C02AA02).
Mechanism of action
Reduces blood pressure via depletion of sympathetic biogenic amines (norepinephrine and dopamine). This also commonly results in sedative effects.
Therapeutic use
Management of mild-to-moderate hypertension. Treatment of agitated psychotic states (schizophrenia).
Pregnancy and lactiation implications
Use with caution during pregnancy and in nursing women.
Unlabeled use
Management of tardive dyskinesia.
Contraindications
Hypersensitivity to reserpine or any component of the formulation. Active peptic ulcer disease, ulcerative colitis. History of mental depression (especially with suicidal tendencies). Patients receiving electroconvulsive therapy.
Warnings and precautions
At high doses, significant mental depression, anxiety, or psychosis may occur. Reserpine may cause orthostatic hypotension (use with caution in risk of hypotension or in cardiovascular disease or cerebrovascular disease). Use with caution in asthma, gallstones, inflammatory bowel disease or history of peptic ulcer disease. Use with caution in Parkinson’s disease, and in renal impairment. Avoid concurrent use of MAOIs and/or drugs with MAO-inhibiting properties. Discontinue reserpine 7 days before electroshock therapy.